NBI-921352 is a Small Molecule owned by Neurocrine Biosciences, and is involved in 7 clinical trials, of which 2 were completed, and 5 are ongoing.
NBI-921352 acts by blocking voltage-gated sodium channel Nav1.6. Voltage-gated sodium channels initiate action potentials in brain neurons and mutations in sodium channels are responsible for epilepsy. Nav1.1 plays a critical role in the normal functioning of inhibitory pathways in the brain. Mutations in one copy of the Nav1.1 voltage-gated sodium channel cause a partial loss of Nav1.1 function. The lack of fully functioning Nav1.1 and inhibitory pathways allows unopposed brain excitatory activity preferentially mediated by the voltage-gated sodium channel Nav1.6 which results in the severe seizures of the disease.
The revenue for NBI-921352 is expected to reach a total of $1.2bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the NBI-921352 NPV Report.
NBI-921352 (XEN-901) is under development for the treatment of rare infantile epileptic encephalopathies such as Dravet syndrome and SCN8A developmental and epileptic encephalopathy (SCN8A-DEE) and focal-onset seizures. It acts by targeting selective Nav1.6. The drug candidate is developed based on extreme genetics platform. It is administered through oral route and formulated as a capsule and granules dosage forms.
Neurocrine Biosciences Overview
Neurocrine Biosciences (Neurocrine) discovers, develops, and sells pharmaceutical products for the treatment of neurologic, psychiatric, and endocrine-related diseases and disorders. Its lead product, Ingrezza (valbenazine) capsule, is a US FDA-approved selective vesicular monoamine transporter 2 inhibitor for the treatment of adults with tardive dyskinesia (TD). The company’s other major pipeline products include elagolix, a gonadotropin-releasing hormone (GnRH) antagonist for the treatment of endometriosis and uterine fibroids, and opicapone, a catechol-O-methyltransferase inhibitor (COMT inhibitor) intended for adult patients with Parkinson’s disease. The company also develops drug candidates for the treatment of essential tremor and classic congenital adrenal hyperplasia. Neurocrine is headquartered in San Diego, California, the US.
The company reported revenues of (US Dollars) US$1,133.5 million for the fiscal year ended December 2021 (FY2021), an increase of 8.4% over FY2020. In FY2021, the company’s operating margin was 9%, compared to an operating margin of 13.8% in FY2020. In FY2021, the company recorded a net margin of 7.9%, compared to a net margin of 38.9% in FY2020. The company reported revenues of US$387.9 million for the third quarter ended September 2022, an increase of 2.6% over the previous quarter.
Quick View – NBI-921352
|Highest Development Stage|